ARA-290
ARA-290 (Cibinetide)
An engineered peptide derived from EPO that repairs damaged nerves and reduces inflammation without affecting red blood cell count, blood pressure, or clotting risk.
ARA-290, also known as cibinetide, is a peptide that helps repair damaged nerves and reduce inflammation without the dangerous side effects of EPO (erythropoietin). If you have heard of EPO, you know it boosts red blood cells -- athletes have abused it for decades. But EPO also has powerful tissue healing and protective effects that scientists wanted to isolate. Researchers figured out which part of the EPO molecule was responsible for healing versus blood cell production, extracted just the healing part, and created ARA-290. The result is a compound that repairs tissue and calms inflammation without touching your red blood cell count, blood pressure, or clotting risk.
This matters particularly for people dealing with neuropathy -- the burning, tingling, and pain in hands and feet that is common in diabetics and people with autoimmune conditions. Most treatments for neuropathy just mask the pain. ARA-290 has shown the ability to actually regrow damaged nerve fibers in clinical trials. Using corneal confocal microscopy, researchers measured a 23 percent increase in nerve fiber area after just 28 days of treatment, meaning nerves were physically regenerating.
ARA-290 has received FDA Orphan Drug designation for sarcoidosis-related neuropathic pain, which means the FDA recognizes it as a promising treatment for a serious condition. Multiple Phase 2 and Phase 3 clinical trials have been completed with positive results. It is not FDA approved for general use and is available as a research chemical.
How It Works
Your body has a receptor system designed specifically for tissue repair called the innate repair receptor. This receptor only appears on cells that are stressed or injured -- healthy cells do not display it. When ARA-290 binds to this receptor, it sends a signal telling the damaged cell to repair itself and survive. This is fundamentally different from regular EPO, which binds to a completely separate receptor that tells your bone marrow to make more red blood cells. ARA-290 does not interact with the red blood cell receptor at all, which is why it provides healing without blood-related side effects.
When you have chronic inflammation, your immune system is stuck in overdrive, producing too many inflammatory signals. ARA-290 dials back this overreaction by reducing inflammatory signaling molecules like TNF-alpha, IL-1, and IL-6. Importantly, it calms the immune overreaction without suppressing your immune system entirely -- you still maintain normal defenses against infections while the harmful excess inflammation is reduced.
The most exciting mechanism is nerve regeneration. In clinical trials, researchers measured nerve fiber density in patients' corneas, which is a non-invasive way to assess small fiber nerve health throughout the body. After 28 days of ARA-290 treatment, patients showed a 23 percent increase in nerve fiber area -- their nerves were actually regrowing. Beyond nerves, ARA-290 also protects kidneys, heart, and lungs from damage caused by reduced blood flow or inflammation, and it does all of this without changing red blood cell count, hematocrit levels, blood viscosity, or blood pressure.
Potential Benefits
Small Fiber Neuropathy Relief
The most robust clinical data for ARA-290 comes from neuropathy studies in both diabetic and sarcoidosis patients. Results show significant reduction in neuropathic pain scores, improved quality of life measurements, measurable increases in nerve fiber density, and benefits that persist during the treatment period. Unlike pain medications that merely mask symptoms, ARA-290 addresses the underlying nerve damage.
Nerve Fiber Regeneration
Using corneal confocal microscopy, researchers demonstrated that ARA-290 actually promotes nerve regrowth with increased corneal nerve fiber area, improved nerve fiber branching, and evidence of small fiber regeneration visible at 28 days. This ability to physically regenerate damaged nerves is what sets ARA-290 apart from conventional neuropathy treatments.
Metabolic Benefits
In Type 2 diabetic patients, ARA-290 showed improved HbA1c (a measure of long-term blood sugar control), better lipid profiles, and enhanced insulin sensitivity. These metabolic improvements occurred alongside the nerve benefits, suggesting the compound has broader effects on diabetic health beyond just treating neuropathy symptoms.
Diabetic Wound Healing
Preclinical and early clinical data suggest ARA-290 may accelerate wound closure in diabetic patients, improve tissue repair capacity, support healing in chronic wounds, and reduce the time to wound resolution. Diabetic wounds are notoriously slow to heal due to nerve damage and poor blood supply, making this a potentially important application.
Inflammation Control Without Immune Suppression
ARA-290 modulates inflammation by reducing pro-inflammatory signaling molecules and calming overactive immune responses, but it does this without broadly suppressing your immune system. This targeted anti-inflammatory effect may benefit autoimmune conditions while maintaining your ability to fight infections.
Pain Relief and Quality of Life
Patients receiving ARA-290 reported reduced pain intensity, improved physical functioning, better sleep quality, reduced need for pain medications, improved energy levels, and enhanced daily activity capacity. These improvements reflect the compound's ability to address the root cause of neuropathic pain rather than simply blocking pain signals.
What the Research Shows
Heij and colleagues conducted a pilot study published in Molecular Medicine in 2012 in which 8 sarcoidosis patients with small fiber neuropathy received ARA-290 for 28 days. The results showed significant improvement in pain scores, increased corneal nerve fiber density, and improved quality of life measures. This was the first study to demonstrate that ARA-290 could actually regenerate nerve fibers in humans, not just reduce symptoms.
Culver and colleagues published a randomized, double-blind, placebo-controlled Phase 2b trial in 2017 in Investigative Ophthalmology and Visual Science, studying 64 patients with diabetic neuropathy. Patients receiving 4 mg daily of ARA-290 for 28 days showed a 23 percent increase in corneal nerve fiber area compared to placebo, with significant improvements in neuropathic symptoms and a good safety profile with no serious adverse events. This rigorously designed trial confirmed the nerve regeneration findings in a much larger patient group.
Brines and colleagues published a 2014 study in Molecular Medicine showing that ARA-290 improved blood sugar control (HbA1c), lipid profiles, and insulin sensitivity in Type 2 diabetic patients while simultaneously improving neuropathy symptoms. Crucially, there was no effect on hematocrit, confirming the absence of EPO-like blood activity. Dahan and colleagues characterized the mechanism in 2016, confirming selective innate repair receptor activation, the absence of any red-blood-cell-stimulating activity, anti-inflammatory effects via cytokine modulation, and tissue-protective effects completely independent of blood effects.
What to Know
ARA-290 has demonstrated a favorable safety profile in clinical trials. The most common side effects are mild headache (usually transient), injection site reactions including redness, swelling, and irritation, mild nausea or digestive discomfort, and occasional dizziness. These were generally mild and did not lead to treatment discontinuation.
The critical safety advantage of ARA-290 is what it does NOT do. Unlike EPO, ARA-290 does not increase red blood cell count or hematocrit, does not elevate blood pressure, does not increase clotting risk, and does not cause polycythemia. None of the serious side effects associated with EPO -- thrombotic events, hypertension, increased cardiovascular risk, or pure red cell aplasia -- were observed in ARA-290 trials.
Exercise caution if you have active cancer, though the innate repair receptor is distinct from tumor growth pathways. Safety data is limited to clinical trials of 28 to 56 days, so long-term effects beyond this period are not yet known. Insufficient data exists for use during pregnancy, breastfeeding, or in severe kidney or liver disease. No significant drug interactions have been identified, and ARA-290 was studied alongside standard diabetic medications without issues.
Research References
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy
Heij L, et al. · Molecular Medicine · 2012
Open-label pilot study in 8 sarcoidosis patients showing ARA-290 produced significant improvement in pain scores, increased corneal nerve fiber density, and improved quality of life measures over 28 days of treatment.
View StudyCibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
Culver DA, Dahan A, Baber D, et al. · Investigative Ophthalmology and Visual Science · 2017
Randomized, double-blind, placebo-controlled Phase 2b trial in 64 patients showing 4 mg daily ARA-290 produced a 23% increase in corneal nerve fiber area versus placebo with significant symptom improvements and no serious adverse events.
View StudyARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Brines M, Dunne AN, van Velzen M, et al. · Molecular Medicine · 2014
Demonstrated ARA-290 improved HbA1c, lipid profiles, insulin sensitivity, and neuropathy symptoms in Type 2 diabetic patients with no effect on hematocrit, confirming the absence of EPO-like erythropoietic activity.
View StudyARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
Dahan A, Dunne A, Swartjes M, et al. · Molecular Medicine · 2013
Confirmed ARA-290's selective innate repair receptor activation and anti-inflammatory effects, with demonstrated improvements in neuropathic symptoms and measurable increases in corneal nerve fiber density in sarcoidosis patients.
View StudyThe receptor that tames the innate immune response
Brines M, Cerami A · Molecular Medicine · 2012
Characterized the innate repair receptor as distinct from the classical erythropoietin receptor, establishing the molecular basis for ARA-290's tissue-protective and anti-inflammatory effects without erythropoietic activity.
View Study